"This is SuperGen's first patent relating to the use of Nipent® in graft-versus-host disease, and it enhances the potential value of our franchise beyond the current approved indication of Hairy Cell Leukemia," said Edward L. Jacobs, Chief Operating Officer. " Nipent® is being studied in a large number of trials in a variety of clinical settings. This patent supports the ongoing efforts of clinical investigators to explore further Nipent's utility in GvHD."
GvHD is a condition that results when the immune cells of a transplant (usually of bone marrow) from a donor attack the tissues of the person receiving the transplant while Nipent® (pentostatin for injection) is currently approved as a single-agent treatment for patients with Hairy Cell Leukemia.
Read more at Supergen, Inc. press release.
.jpg)
Comment Preview